Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy

Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy

We aimed to develop an antibody panel and data analysis algorithm for multicolor flow cytometry (MFC), which is a reliable method for minimal residual disease (MRD) detection in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treated with CD19-directed therapy. The development...

Full description

Bibliographic Details
Main Authors: Ekaterina Mikhailova, Olga Illarionova, Alexander Komkov, Elena Zerkalenkova, Ilgar Mamedov, Larisa Shelikhova, Yulia Olshanskaya, Natalia Miakova, Galina Novichkova, Alexander Karachunskiy, Michael Maschan, Alexander Popov
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
minimal residual disease
flow cytometry
blinatumomab
CAR-T cells
Online Access:https://www.mdpi.com/2072-6694/14/21/5445

Internet

https://www.mdpi.com/2072-6694/14/21/5445

Similar Items